Literature DB >> 16238582

Secretory immunoglobulin A obtained from pooled human colostrum and milk for oral passive immunization.

Cristiane B Carbonare1, Solange B Carbonare, Magda M S Carneiro-Sampaio.   

Abstract

Passive immunization is useful in cases of immunodeficiencies or infectious diseases, but usually seric gammaglobulin or hyperimmune sera are administered parenterally, providing good systemic immunization, though with low protection of the mucosal surfaces. The oral administration of secretory antibodies, especially surface immunoglobulin (SIg)A, which is perfectly adapted to the mucosal environment, would therefore, be preferable. The aim of the present study was to obtain a SIgA preparation from pooled human colostrum and milk, which should maintain the essential properties of the antibodies suitable for clinical oral administration. IgA preparations were obtained from colostrum and milk pools by salt precipitation. The final products were evaluated in terms of yield and purity, as well as antibody activity to bacterial antigens and toxins and inhibitory activity of bacterial adhesion to epithelial cells. The best yield and purity were achieved when the colostrum pool was used as a source of IgA; the final product showed very few bands of protein contamination. The IgA preparations preserved the antibody reactivity against various microbial antigens, well comparable with the reactivity exhibited by the original milk and colostrum pools. SIgA preparations were able to inhibit greatly the adhesion of enteropathogenic Escherichia coli to Hep-2 cells and the invasion of enteroinvasive E. coli. These promising results show the feasibility of obtaining SIgA suitable for oral use, which may in future be administered to immunodeficient patients with gastrointestinal manifestations, from human colostrum and milk.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16238582     DOI: 10.1111/j.1399-3038.2005.00332.x

Source DB:  PubMed          Journal:  Pediatr Allergy Immunol        ISSN: 0905-6157            Impact factor:   6.377


  6 in total

1.  Recognition of gram-positive intestinal bacteria by hybridoma- and colostrum-derived secretory immunoglobulin A is mediated by carbohydrates.

Authors:  Amandine Mathias; Blaise Corthésy
Journal:  J Biol Chem       Date:  2011-03-21       Impact factor: 5.157

2.  Human plasma-derived polymeric IgA and IgM antibodies associate with secretory component to yield biologically active secretory-like antibodies.

Authors:  Stéphanie Longet; Sarah Miled; Marius Lötscher; Sylvia M Miescher; Adrian W Zuercher; Blaise Corthésy
Journal:  J Biol Chem       Date:  2012-12-18       Impact factor: 5.157

3.  Detection of secretory immunoglobulin A in human colostrum as mucosal immune response against proteins of the type III secretion system of Salmonella, Shigella and enteropathogenic Escherichia coli.

Authors:  David Durand; Theresa J Ochoa; Sicilia M E Bellomo; Carmen A Contreras; Víctor H Bustamante; Joaquim Ruiz; Thomas G Cleary
Journal:  Pediatr Infect Dis J       Date:  2013-10       Impact factor: 2.129

4.  Microbiota-targeted maternal antibodies protect neonates from enteric infection.

Authors:  Wen Zheng; Wenjing Zhao; Meng Wu; Xinyang Song; Florence Caro; Ximei Sun; Francesca Gazzaniga; Giuseppe Stefanetti; Sungwhan Oh; John J Mekalanos; Dennis L Kasper
Journal:  Nature       Date:  2020-01-08       Impact factor: 69.504

5.  Alteration of DSS-mediated immune cell redistribution in murine colitis by oral colostral immunoglobulin.

Authors:  Peggy Bodammer; Elisabeth Zirzow; Sebastian Klammt; Claudia Maletzki; Claus Kerkhoff
Journal:  BMC Immunol       Date:  2013-02-20       Impact factor: 3.615

6.  Systemic administration of an HIV-1 broadly neutralizing dimeric IgA yields mucosal secretory IgA and virus neutralization.

Authors:  Joshua Eudailey; Erika L Kunz; Genevieve G Fouda; Joshua D Amos; Brooke E Liebl; Jonathan Himes; Felix Boakye-Agyeman; Krista Beck; Anthony J Michaels; Michael Cohen-Wolkowiez; Barton F Haynes; Keith A Reimann; Sallie R Permar
Journal:  Mucosal Immunol       Date:  2016-04-13       Impact factor: 7.313

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.